Restless legs affect many people with MS, review finds
By MS Buddy ·
Summarized from JAMA, Jan 2026 · PubMed · DOI. AI-generated summary. Not medical advice.
Review · people with restless legs syndrome, including people with MS
Research by John Winkelman and Benjamin Wipper at Brigham and Women's Hospital.
How common is restless legs syndrome in people with MS?
Key Takeaway
A review found that restless legs syndrome is common in people with MS and can disrupt sleep.

What They Found
Restless legs syndrome causes a strong urge to move, usually in the legs. Unpleasant feelings, such as aching or tingling, often come with it. Symptoms tend to worsen while resting and improve during movement, especially in the evening or at night. The review reported restless legs syndrome in about 28% of people with MS. Across the studies reviewed, about 70% of people taking certain nerve-pain medicines reported major improvement, compared with about 40% taking a placebo (an inactive treatment).
Who Should Care and Why
This review covers people with restless legs syndrome, including people with MS. Its findings about treatments are not specific to people with MS. Restless legs symptoms can make it hard to fall asleep or stay asleep. The review also describes how doctors identify the condition from a person's symptoms. It reports that some medicines used for restless legs can make symptoms worse over time.
Important Considerations
You should know this is a review, not a new study testing a treatment in people with MS. The abstract does not give a total number of people included in the studies it reviewed. You cannot tell from this abstract whether the reported treatment results apply equally to people with MS.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in JAMA by . Reproduced from the PubMed record.
Restless legs syndrome (RLS) is a sleep-related movement disorder that affects approximately 3% of US adults to a clinically significant extent and can cause substantial sleep disturbance. Restless legs syndrome is characterized by an overwhelming urge to move the limbs, typically the legs, often accompanied by unpleasant limb sensations (eg, achiness, tingling). Symptoms, provoked by immobility, are relieved while moving and are typically present or most severe in the evening or at night. Restless legs syndrome symptoms may lead to difficulty falling asleep, staying asleep, or returning to sleep. According to population-based studies, approximately 8% of US adults experience RLS symptoms of any frequency annually and 3% experience moderately or severely distressing symptoms at least twice weekly. Patients with RLS have impaired quality of life and elevated rates of cardiovascular disease (29.6% with coronary artery disease, stroke, or heart failure), depression (30.4%), and suicidal ideation or self-harm (0.35 cases/1000 person-years). Restless legs syndrome is common among patients with multiple sclerosis (27.5%), end-stage kidney disease (24%), and iron deficiency anemia (23.9%); during pregnancy and especially in the third trimester (22%); with peripheral neuropathy (eg, diabetic, idiopathic; 21.5%); and with Parkinson disease (20%). Other risk factors include family history of RLS, northern European descent, female sex (2:1 vs male sex), and older age (RLS prevalence of 10% in adults ≥65 years). Restless legs syndrome is diagnosed based on clinical history; polysomnography is not recommended for diagnosis. Iron supplementation with ferrous sulfate (325-650 mg daily or every other day) or intravenous iron (1000 mg) should be initiated for serum ferritin level less than or equal to 100 ng/mL or transferrin saturation less than 20%. If possible, medications associated with RLS, including serotonergic antidepressants, dopamine antagonists, and centrally acting H1 antihistamines (eg, diphenhydramine), should be discontinued. Gabapentinoids (eg, gabapentin, gabapentin enacarbil, pregabalin) are first-line pharmacologic therapy. In randomized clinical trials, approximately 70% of patients treated with gabapentinoids had much or very much improved RLS symptoms vs approximately 40% with placebo (P < .001). Dopamine agonists (eg, ropinirole, pramipexole, rotigotine) are no longer recommended as first-line medications due to the risk of augmentation, an iatrogenic worsening of RLS symptoms, which has an annual incidence of 7% to 10% with these medications. Patients who do not improve with first-line treatment or have augmented RLS often benefit from low-dose opioids (eg, methadone 5-10 mg daily). Restless legs syndrome affects approximately 3% of adults and can have negative effects on sleep and quality of life. Initial management includes cessation of exacerbating medications, as well as iron supplementation for patients with low-normal iron indices. If medication therapy is indicated, gabapentinoids are first-line treatment.
Categories
Explore more research
Related MS research

11/20/2026
In a trial of 90 adults with MS, adding fatigue-focused talk therapy to supervised Pilates improved
Read More
11/20/2026
A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac
Read More
11/20/2026
A small study followed brain connections and thinking in early MS over 10 months. Patterns differed
Read More
11/19/2026
In a study of 379 people with MS and walking difficulties, home and facility exercise had similar wa
Read More
11/19/2026
Six fatigue questionnaires gave similar group results in MS, but individual scores differed for up t
Read More
11/17/2026
A review suggests MS fatigue may reflect extra effort to control movement and incomplete recovery af
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
